Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro

Virology. 2007 Jul 5;363(2):447-53. doi: 10.1016/j.virol.2007.02.011. Epub 2007 Mar 13.


Although the majority of primary HIV-1 variants can be neutralized by broadly neutralizing antibodies such as b12, 2G12, 2F5 and 4E10, resistance to these antibodies has been reported as well. The ability of the broadly neutralizing antibodies to inhibit a variety of viruses suggests that their epitopes are conserved and escape from these antibodies may thus come at a cost to viral fitness. Here we demonstrate that resistance to broadly neutralizing antibodies was in general not associated with a reduced replicative capacity of the virus in vitro. This indicates that loss of replicative capacity due to escape from broadly neutralizing antibodies may be limited.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / pharmacology
  • Drug Resistance, Viral
  • Epitopes / immunology
  • Genetic Variation*
  • HIV Antibodies / immunology
  • HIV Antibodies / pharmacology*
  • HIV Infections / virology*
  • HIV-1 / drug effects
  • HIV-1 / pathogenicity*
  • HIV-1 / physiology*
  • Humans
  • Microbial Sensitivity Tests
  • Neutralization Tests
  • Virulence / genetics
  • Virus Replication


  • Antibodies, Monoclonal
  • Epitopes
  • HIV Antibodies